Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...
Being laid off is bad enough. When companies mishandle the layoff process, it can make the situation even worse. Four ...
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...
Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...
BioSpace presents 25 noteworthy biopharma startups in ’25; analysts forecast stronger M&A as the J.P. Morgan Healthcare ...